首页> 外文期刊>Qatar Medical Journal >The role of serum surfactant protein D as a biomarker of exacerbation of chronic obstructive pulmonary disease
【24h】

The role of serum surfactant protein D as a biomarker of exacerbation of chronic obstructive pulmonary disease

机译:血清表面活性剂蛋白D作为慢性阻塞性肺疾病加重的生物标志物的作用

获取原文
       

摘要

Background: The exacerbation of chronic obstructive pulmonary disease (COPD) is a major factor for the high mortality associated with the disease. There is a paucity in the lung-specific biomarkers which diagnose these exacerbations. Surfactant protein D (SP-D) is a promising biomarker in predicting clinical outcomes for patients with COPD, is lung-specific and can be detected in serum. However, the profile in which serum concentrations of SP-D change during acute exacerbation is still unclear. This study aims to estimate and compare the concentrations of serum SP-D in patients with stable disease and during the exacerbation. Methods: A cross-sectional study was conducted which composed of apparently healthy individuals (n = 28), which included 14 smokers and 14 nonsmokers, patients with stable COPD (n = 28), and patients experiencing acute exacerbations (n = 28). Pulmonary functions were performed for all groups. Serum SP-D concentrations were measured using enzyme-linked immunosorbent assay (ELISA). These concentrations were compared by analysis of variance. Results: Serum SP-D levels were significantly elevated in patients with acute exacerbations (508.733 ± 102.813 ng/ml) compared to patients with stable COPD (337.916 ± 86.265 ng/ml) and healthy subjects (177.313 ± 46.998 ng/ml; p < 0.001). Serum SP-D levels correlated inversely with lung function parameters including FEV1%pred, FVC%pred and FEV1/FVC. Conclusion: Serum SP-D levels are raised early on during acute exacerbations of COPD, which could be a potential early diagnostic biomarker for COPD exacerbations.
机译:背景:慢性阻塞性肺疾病(COPD)的恶化是与该疾病相关的高死亡率的主要因素。诊断这些病情恶化的肺特异性生物标志物很少。表面活性剂蛋白D(SP-D)是预测COPD患者临床结局的有前途的生物标志物,具有肺特异性,可以在血清中检测到。但是,尚不清楚在急性发作期间血清SP-D浓度发生变化的情况。这项研究旨在估计和比较疾病稳定期和病情加重期间血清SP-D的浓度。方法:进行了一项横断面研究,该研究由貌似健康的个体(n = 28)组成,其中包括14位吸烟者和14位非吸烟者,COPD稳定的患者(n = 28)和经历急性加重的患者(n = 28)。所有组均进行肺功能检查。使用酶联免疫吸附测定(ELISA)测量血清SP-D浓度。通过方差分析比较这些浓度。结果:与稳定COPD患者(337.916±86.265 ng / ml)和健康受试者(177.313±46.998 ng / ml)相比,急性加重患者的血清SP-D水平显着升高(508.733±102.813 ng / ml)。 0.001)。血清SP-D水平与肺功能参数(包括FEV1%pred,FVC%pred和FEV1 / FVC)成反比。结论:在COPD急性加重期早期,血清SP-D水平升高,这可能是COPD加重的潜在早期诊断生物标志物。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号